DNAe. The first true point-of-need Next-Generation Sequencing company.

DNae. The first true point-of-need Next-Generation Sequencing company.

Our mission is to bring dramatic, life-changing improvements to healthcare and beyond with fast, simple and scientifically sound products. To this end, we apply the best scientific skills and energy to build an evolving and innovative suite of electronic microchip-based solutions that delivers faster, simpler and more cost-effective DNA analysis.

Regius Professor Chris Toumazou FRS, FREng, FMedSci founded the company in 2003, as a spin-out from Imperial College London, having invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. This optics-free, label-free method shifted DNA sequencing from specialized, expensive genome centres into the mainstream of local labs and primary care clinics.

Since its foundation, our company has grown to encompass the vast range of disciplines required to build molecular interfaces and assays on a semiconductor platform. Our core competencies in electronic engineering, molecular biology, fluidics and chemistry make us a force to be reckoned with. A force for good.

Headquartered in London, UK, and operating from Washington, DC, our company expanded operations further in 2015 with a clinical diagnostic development site in San Diego, CA.

DNAe is committed to consistently providing high quality products and services for its customers and meeting regulatory requirements through adherence to its established Quality Management System and a commitment to maintaining its effectiveness.

Senior Management Team

Board of Directors

Samuel Reed

An experienced leader of organizations and teams that are commercializing new products based on innovative technologies. Eighteen years of leadership and management experience – majority of which in medical diagnostics, point-of-care, or sequencing. From early research through FDA clearance and market success. Has led operations as well as supporting external clients – from blue chips to start ups.

Tan Sri Lim Kok Thay

Director Tan Sri Lim Kok Thay is the Chairman and Chief Executive of Genting Berhad, the holding company of the Genting Group. The Genting Group is one of Asia’s most dynamic conglomerates and is involved in leisure and hospitality, power generation, oil palm plantations, property development, biotechnology and oil and gas business activities. These business activities are undertaken by the Group’s key companies, namely Genting Malaysia Berhad, Genting Singapore Plc, Genting Hong Kong Limited, Genting Plantations Berhad and the Genting Energy division.

Professor Christofer Toumazou

Professor Christofer Toumazou‘s (FRS, FREng, FIEEE, FIET, FRSM, FCGI, CEng, Deng, PhD) dedication to bringing semiconductor solutions to healthcare is a long and accomplished one. He established himself as a respected scientist early in his career with the invention and development of an entirely novel concept of current-mode analogue circuitry for ultra-low-power electronic devices for which he was made Professor at Imperial College at 33, one of the youngest in history. Since then he has gone on to publish over 700 research papers and holds over 50 patents in the field semiconductors and healthcare. He is also the Founding Director and Chief Scientist at The Institute of Biomedical Engineering Imperial College London; Founder of Toumaz Technology; Director of the Winston Wong Centre for Bio Inspired Technology, and Professor of Bio-Inspired Technology. His recent awards include: 2011 IET JJ Thomson Medal, 2009 World Technology Award, and the UK’s highest honour in science-Fellowship of the Royal Academy of Engineering and Fellowship of the Royal Society. In recognition of Chris’ invention of the semiconductor DNA sequencing technology he was awarded the Royal Society Gabor Medal (2013), won the 2014 European Inventor Award from the EPO and the IET’s highest accolade, the Faraday Medal (2014) along with the IEEE Biomedical Engineering Award for 2015 and 2016 The European Electronics Industry (ELEKTRA) Life Time Achievement Award.

Tan Kong Han

Kong Han TAN was appointed as President and Chief Operating Officer of Genting Berhad in 2007 and Executive Director in 2020. Genting Berhad is the holding company of the Genting Group, which is involved in leisure and hospitality, oil palm plantations, power generation, oil and gas, property development, life sciences and biotechnology activities, with operations spanning across the globe, including in Malaysia (the Group’s country of origin), Singapore, Indonesia, India, China, the United Kingdom and United States of America.
The Genting Group comprises Genting Berhad (KLSE: Genting) and its listed companies Genting Malaysia Berhad (KLSE: GENM), Genting Plantations Berhad (KLSE: GENP) and Genting Singapore Limited (SGX: G13), as well as principal unlisted subsidiaries Genting Energy Limited and Resorts World Las Vegas LLC.

Tan is also the Chief Executive and Executive Director of Genting Plantations Berhad and oversees the Energy Division of the Genting Group.

Prior to joining Genting Berhad in 2007, Tan worked as an investment banker for more than 13 years and in a Malaysian power generation, entertainment and real estate conglomerate from 2003 to 2007. He is a qualified Barrister at Law, Lincoln’s Inn. He holds a MA from the University of Cambridge.

Clinical Advisory Board

Stephan Harbarth, MD, MS

Associate Professor of Medicine, Associate Epidemiologist, Senior Consultant in Infectious Diseases, Infection Control Programme Geneva University Hospitals and Faculty of Medicine, Geneva, CH

Stephan Harbarth earned his medical degree from Ludwig-Maximilians-University in Munich in 1993 and completed his residency in internal medicine and tropical medicine at Munich University Hospitals. After serving as a clinical fellow in the Infectious Diseases Division and Infection Control Program in the Department of Internal Medicine at Geneva University Hospitals, Dr Harbarth completed his master’s degree in epidemiology at Harvard University in Boston. He is board certified in infectious diseases and was appointed associate professor at the University of Geneva in 2010. Dr Harbarth’s work has garnered several awards, including the ICAAC/ASM Young Investigator Award (2003), the Young Investigator Award from ESCMID (2006), the Swiss Society for Infectious Diseases Award for epidemiological research (2008, 2011), and the SHEA Investigator Award (2011). Dr Harbarth’s group is currently conducting several clinical and epidemiological studies to evaluate key questions related to the control of the acquisition, transmission and infection by multidrug-resistant microorganisms. They participate in several ongoing large-scale EU-funded studies to address this public health threat and collaborate closely with the Genomics Research Laboratory at HUG, based on a productive translational research platform.

Paul Dark, BSc, MBChB, PhD, FRCS, FRCEM, FFICM

Chair in Critical Care Medicine, University of Manchester Professor of Critical Care Medicine & Honorary NHS Consultant, Salford Royal NHS Foundation Trust NIHR CRN National Research Lead for Critical Care, King’s College London, London, UK

Paul Dark, BSc, MD, PhD, FRCS, FRCEM, FFICM, originally studied physics and then medicine. Graduating from The Manchester Medical School, he went on to study clinical academic surgery, emergency medicine and critical care at the Universities of Glasgow and Manchester in the UK, and at the Catholic University of Leuven, Belgium. He was a MRC Clinical Training Fellow, completing his PhD supervised by Professor Rod Little at the UK’s MRC Trauma Unit. Dr. Dark was appointed to his current clinical academic post at the University of Manchester in 2003, carrying out clinical duties in Critical Care Medicine at Salford Royal NHS Foundation Trust, one of the largest services in the UK. He holds senior academic leadership positions at the University of Manchester focused on developing postgraduate learning in research and innovation in acute healthcare. In addition, he leads a programme of work funded by the National Institute of Health Research (NIHR) developing and assessing the diagnostic utility of emerging molecular technologies in the setting of sterile tissue injury and severe infection – focused on matrices in blood and breath. Funded by Innovate UK (formerly Technology Strategy Board) Dr. Dark has led a programme of work developing novel technologies aimed at rapid point-of-care infection/sepsis diagnosis. He advises NICE on diagnostic technology appraisals in sepsis and he leads multi-centre pragmatic clinical trials aimed at developing an improved evidence base for the management of sepsis.